Dicerna (DRNA): Partnerships Expected to Follow After Settlement - SunTrust
Tweet Send to a Friend
SunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $15 price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
